<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01095809</url>
  </required_header>
  <id_info>
    <org_study_id>EBEV</org_study_id>
    <nct_id>NCT01095809</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety and Tolerability of Repeated Dosis of Intravitreous Bevacizumab in Uveitic Macular Oedema</brief_title>
  <acronym>EBEV</acronym>
  <official_title>Open , Randomized Study About Efficacy, Safety and Tolerability od Repeated Dosis of Intravitreous Bevacizumab in Patients With Uveitic Macular Oedema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether intravitreous bevacizumab or intravitreous
      triamcinolone acetonide are effective and safe in the treatment of uveitic macular oedema
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    New intraocular steroid in the market. Recruitment no longer ethical.
  </why_stopped>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">April 2013</completion_date>
  <primary_completion_date type="Anticipated">April 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Macular Thickness Measurements Using Stratus Optical Coherence Tomography</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>visual acuity</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intraocular pressure</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>opacity crystalline</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Uveitis</condition>
  <arm_group>
    <arm_group_label>bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intravitreous bevacizumab 2,5 mg at baseline, week 4 and 8. reinjection is required.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>triamcinolone acetonide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intravitreous triamcinolone 2 mg, frequency: 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>2.5mg at baseline, week 4 and 8. Beyond this initial period if needed reinjection criteria are described in protocol</description>
    <arm_group_label>bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triamcinolone acetonide</intervention_name>
    <description>2 mg at baseline; frequency every three months if needed. reinjection criteria are described in protocol</description>
    <arm_group_label>triamcinolone acetonide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patients with uveitis or retinal vasculitis with unilateral or bilateral macular
             oedema

          -  with macular thickness &gt; 250 micra using OCT

          -  visual acuity at least 20/200

          -  with stable treatment with oral prednisone at least during 3 months, either oral
             ciclosporin or other immunomodulator to treat intraocular inflammatory disease

          -  patient that can follow study's requirements

          -  patient who consents to participate

        Exclusion Criteria:

          -  presence of corneal or crystalline opacity preventing observation of fundus of eye

          -  patients requiring ocular surgery in next 3 months

          -  one-eyed

          -  pregnancy and child breastfeeding

          -  previous history of glaucoma

          -  on treatment woth an experimental ocular drug

          -  previous thromboembolism or receiving oral anticoagulant treatment

          -  vitrectomy

          -  patients with proved tractional macular pathology associated to macular oedema
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital de Son Dureta</name>
      <address>
        <city>palma de Mallorca</city>
        <state>Spain/ Baleares</state>
        <zip>07014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <state>Spain/ catalonia</state>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Vissum Alicante</name>
      <address>
        <city>Alicante</city>
        <state>Spain/ Com. Valenciana</state>
        <zip>03016</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <state>Spain/Catalonia</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic of Barcelona</name>
      <address>
        <city>Barcelona</city>
        <state>Spain/Catalonia</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2010</study_first_submitted>
  <study_first_submitted_qc>March 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2010</study_first_posted>
  <last_update_submitted>March 22, 2012</last_update_submitted>
  <last_update_submitted_qc>March 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2012</last_update_posted>
  <responsible_party>
    <name_title>Alfredo Manuel Adan Civera</name_title>
    <organization>Hospital Clinic of Barcelona</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Uveitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

